{
    "data": [
        {
            "id": "tag:reuters.com,2026:newsml_L6N3ZN11A:0",
            "title": "US lifts sanctions on top Malian officials as ties improve ",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>    The U.S. has lifted sanctions targeting three senior Malian officials for their relationship with Russia's mercenary group Wagner, according to a notification from the Treasury Department, as bilateral relations improve.</span></p><p class=\"\"><span>The Trump administration has brushed aside concerns about dealing with military-led governments in Africa's Sahel region, aiming instead to focus on shared interests like the growing potency of jihadist groups. </span></p><p class=\"\"><span>The Malian officials delisted on Friday included Defense Minister Sadio Camara and senior military officials Alou Boi Diarra and Adama Bagayoko. All had been sanctioned for their connections to the now largely defunct Wagner mercenary group, which Russia has since folded into its Africa Corps.  </span></p><p class=\"\"><span>There was no immediate response from the Malian government. </span></p><p class=\"\"><span>The top U.S. envoy to Africa, Nick Checker, visited Mali last month to discuss the next steps for building closer ties, according to the State Department. Last year, Washington moved to resume intelligence sharing with Mali to support counterterrorism efforts.</span></p><p class=\"\"><span>Cameron Hudson, a former U.S. official who worked on Africa at the Central Intelligence Agency and State Department, said the move appeared to be part of a broader effort to re-engage with the Sahel.</span></p><p class=\"\"><span>     \"The U.S. in recent months has substantially increased its engagement with Malian authorities in an effort to restart counterterrorism cooperation and to further underline the message that the U.S. will no longer be hamstrung in its foreign policy by disengaging in countries run by military juntas,\" he told Reuters.</span></p><p class=\"\"><span>Under the Biden administration, the U.S. lost its main spy base in the region, in neighbouring Niger, and was banned from carrying out intelligence-gathering flights, severely hobbling its ability to monitor and counter jihadists there. </span></p><p class=\"\"><span>Mali, along with its Sahel neighbours Burkina Faso and Niger, has struggled to beat back an expanding, decade-long jihadist insurgency led by local groups allied to al Qaeda and Islamic State. The violence has spread to coastal nations and is causing a growing number of casualties.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L6N3ZN11A:0-us-lifts-sanctions-on-top-malian-officials-as-ties-improve/",
            "pub_date": "2026-02-28 02:12:04",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tradingview:2b7a40ee6888d:0",
            "title": "UFP Technologies updates investor presentation, lays out 3–5yr targets including 12–18% revenue growth",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>UFP Technologies released updated investor presentation highlighting strategic focus on MedTech and 3–5 year financial targets.</span></strong></p><span> </span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Key Highlights:</span></strong></p><span> </span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Filed Exhibit 99.1: updated presentation for investor meetings and public presentations; disclosure not \"filed\" under Section 18.</span></li><li class=\"listItem-bmN0_SHH\"><span>Company emphasizes MedTech focus: ~92% of $603M revenue comes from medical device customers and 26 of top 30 OEMs are clients.</span></li><li class=\"listItem-bmN0_SHH\"><span>3–5 year targets: 12–18% revenue growth, 28–31% gross margin, and 17–20% adjusted operating margin.</span></li><li class=\"listItem-bmN0_SHH\"><span>Growth strategy: organic focus on high-growth MedTech niches plus strategic, accretive acquisitions (22 completed historically).</span></li><li class=\"listItem-bmN0_SHH\"><span>Highlights market opportunity in robotic surgery and CDMO segments; cites global medical device market growth and scale advantages.</span></li></ul><p class=\"\"><span>Original SEC Filing: </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://www.sec.gov/Archives/edgar/data/914156/000162828026012667/ufpt-20260227.htm\" rel=\"nofollow\" target=\"_blank\">UFP TECHNOLOGIES INC [ UFPT ] - 8-K - Feb. 27, 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/tradingview:2b7a40ee6888d:0-ufp-technologies-updates-investor-presentation-lays-out-3-5yr-targets-including-12-18-revenue-growth/",
            "pub_date": "2026-02-28 02:13:01",
            "source": "TradingView",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tradingview:a13201c382853:0",
            "title": "Caliber completes sale of Holiday Inn Ocotillo for $13.0M, positions Hospitality Trust for 2026 expansion",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Caliber sold the Holiday Inn Ocotillo for $13.0 million and will recycle proceeds to expand Caliber Hospitality Trust in 2026.</span></strong></p><span> </span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Key Highlights:</span></strong></p><span> </span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Sold Holiday Inn Ocotillo in Phoenix–Chandler submarket for $13.0 million; asset was owned by Caliber Hospitality Trust.</span></li><li class=\"listItem-bmN0_SHH\"><span>Proceeds will be recycled and combined with new equity from in-house capital markets and institutional partners to grow CHT.</span></li><li class=\"listItem-bmN0_SHH\"><span>CHT will pursue branded, cash-flowing hotels via tax-efficient contributions, value-add acquisitions, select development, and partnerships.</span></li><li class=\"listItem-bmN0_SHH\"><span>Caliber expects growth of CHT to drive recurring asset management fees, performance incentives, and potential balance sheet participation.</span></li><li class=\"listItem-bmN0_SHH\"><span>CHT may evaluate liquidity options as it scales, including a non-traded REIT and a longer-term public listing objective.</span></li></ul><p class=\"\"><span>Original SEC Filing: </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://www.sec.gov/Archives/edgar/data/1627282/000162728226000004/cwd-20260227.htm\" rel=\"nofollow\" target=\"_blank\">CaliberCos Inc. [ CWD ] - 8-K - Feb. 27, 2026</a></p><section class=\"variant-secondary-aHOVUrmQ disclaimer-fdvjGD1u\"><b class=\"heading-wrapper-aHOVUrmQ\"><span class=\"heading-aHOVUrmQ\">Disclaimer</span></b><div class=\"content-aHOVUrmQ link-with-underline-aHOVUrmQ\"><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>",
            "link": "https://www.tradingview.com/news/tradingview:a13201c382853:0-caliber-completes-sale-of-holiday-inn-ocotillo-for-13-0m-positions-hospitality-trust-for-2026-expansion/",
            "pub_date": "2026-02-28 02:13:01",
            "source": "TradingView",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008816:0",
            "title": "Sweetgreen Is Maintained at Outperform by RBC Capital",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:14 GMT) </span></strong><span>Sweetgreen Price Target Cut to $7.00/Share From $8.00 by RBC Capital</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008816:0/",
            "pub_date": "2026-02-28 02:14:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008813:0",
            "title": "SBA Communications Is Maintained at Equal-Weight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:14 GMT) </span></strong><span>SBA Communications Price Target Cut to $195.00/Share From $205.00 by Wells Fargo</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008813:0/",
            "pub_date": "2026-02-28 02:14:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008818:0",
            "title": "Invitation Homes Cut to Market Perform From Outperform by Raymond James",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008818:0/",
            "pub_date": "2026-02-28 02:14:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008815:0",
            "title": "Essex Property Cut to Market Perform From Outperform by Raymond James",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008815:0/",
            "pub_date": "2026-02-28 02:14:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "dpa_afx:9a1ec4d7bd71e:0",
            "title": "European Stocks Close On Mixed Note",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - European stocks turned in a mixed performance on Friday with investors digesting a slew of economic data from the region, and earnings announcements and other corporate news.</span></p><p class=\"\"><span>Geopolitical news was in focus as well, and the mood in most of the markets remained somewhat cautious amid lingering concerns about workforce disruption due to artificial-intelligence related layoffs.</span></p><p class=\"\"><span>The pan European Stoxx 600 gained 0.19%. The U.K.'s FTSE 100 climbed 0.59%, Germany's DAX edged up 0.09%, and France's CAC 40 ended down by 0.47%. Switzerland's SMI closed up by 0.72%.</span></p><p class=\"\"><span>Among other markets in Europe, Austria, Czech Republic, Greece, Iceland, Ireland, Poland, Spain and Türkiye ended weak.</span></p><p class=\"\"><span>Finland, Netherlands, Norway, Russia closed Sweden notably higher, while Belgium, Denmark and Portugal edged up marginally.</span></p><p class=\"\"><span>In the UK market, RightMove gained about 4.3%.</span></p><p class=\"\"><span>Diageo, BT Group, LSEG, Fresnillo, Haleon, AstraZeneca, Coca-Cola Europacific Partners, Airtel Africa, Relx, Endeavour Mining, Howden Joinery Group, Reckitt Benckiser, Unilever, Smiths Group, Glencore, Next, Beazley, Centrica and Shell gained 1.7%-5%.</span></p><p class=\"\"><span>Melrose Industries plunged 11.6% after it forecast 2026 revenue below expectations.</span></p><p class=\"\"><span>IAG shed about 7.4%. The stock moved up sharply earlier in the session after the company issued a positive outlook and announced a 1.5 billion euro repurchase plan.</span></p><p class=\"\"><span>Hikma Pharmaceuticals, Barclays, Intercontinental Hotels Group, Entain, Easyjet, Burberry Group, Lloyds Banking Group, ICG and Metlen Energy &amp; Metals lost 2%-4.3%.</span></p><p class=\"\"><span>In the German market, Scout24 climbed nearly 4.5%. Deutsche Telekom moved up 3.7% and Deutsche Boerse gained nearly 3%.</span></p><p class=\"\"><span>Merck, Symrise, Vonovia, Munich RE, Qiagen, Beiersdorf, Hannover Rueck, Daimler Truck Holding, Gea Group and Siemens Energy also posted strong gains.</span></p><p class=\"\"><span>BASF declined sharply after the company forecast flat earnings this year. Delivery Hero ended sharply lower after reporting annual gross merchandise value (GMV) slightly below market expectations.</span></p><p class=\"\"><span>Commerzbank, Deutsche Bank, Addas, Continental, Infineon and MTU Aero Engines also closed notably lower.</span></p><p class=\"\"><span>In the French market, Pernod Ricard, Stellantis, Capgemini, Unibail Rodamco, Schneider Electric, Sanofi, AXA, Orange, Veolia Environment, Dassault Systemes, Eurofins Scientific, Michelin and Bouygues closed notably higher.</span></p><p class=\"\"><span>EssilorLuxottica shed about 5.5%. Societe Generale, STMicroelectronics, Credit Agricole, Engie, Safran, Airbus and Accor ended lower by 1%-2%.</span></p><p class=\"\"><span>Preliminary data showed Germany's import prices rose at a faster than expected pace in January but remained lower in year-on-year comparison due to the steep fall in energy prices, a report from the statistical office Destatis said.</span></p><p class=\"\"><span>The import price index rose 1.1% month-on-month, same as in December, data showed. Economists had expected an increase of 0.6%. This was the largest month-on-month increase recorded since January 2025, which was also 1.1%, the statistical office said.</span></p><p class=\"\"><span>Import prices fell 2.3% year-on-year, same as in December.</span></p><p class=\"\"><span>In January, energy prices slumped 21.1% year-on-year but rose 3.5% from the previous month.</span></p><p class=\"\"><span>Germany's seasonally adjusted unemployment rate remained unchanged at 6.3% in February 2026, underscoring the continued strain from three years of economic weakness on Europe's largest labor market. On a non-seasonally adjusted basis, unemployment fell by 14,700 to 3.07 million, easing from January's near 12-year high of 3.08 million.</span></p><p class=\"\"><span>INSEE said France's annual inflation rate accelerated to 1% in February 2026, up from 0.3% in January which was the lowest reading since December 2020, according to preliminary estimates. Compared to the previous month, the CPI went up 0.7%, the most in two years, after a 0.3% gain in January.</span></p><p class=\"\"><span>France's economy expanded 0.2% quarter-on-quarter in Q4 2025, easing from 0.5% in Q3 and confirming preliminary estimates, a separate report from INSEE showed. This marked the softest quarterly growth in three quarters. On an annual basis, GDP expanded 1.2%, higher than initial data of 1.1% and the strongest since Q1 2024, picking up from 1% in Q3. For the full year 2025, the French economy grew 0.9%, slowing from 1.1% in 2024.</span></p><p class=\"\"><span>Meanwhile, French domestic producer prices rose by 0.5% month-on-month in January 2026, following an upwardly revised 0.3% increase in the previous month. This marked the fourth straight month of growth. On an annual basis, the decline in producer prices intensified, dropping 2.3%, the sharpest since December 2024, compared with a 1.9% fall in December.</span></p><p class=\"\"><span>Non Farm Payrolls in France increased by 27073 thousand in December of 2025, another data from INSEE showed.</span></p><p class=\"\"><span>The U.K. consumer confidence index fell to a three-month low or -19 in February, from -16 in January, the Consumer Confidence Barometer survey by the GfK and the Nuremberg Institute for Market Decisions (NIM) revealed. Economists had expected a mild increase to -15.</span></p><p class=\"\"><span>Copyright(c) 2026 RTTNews.com. All Rights Reserved</span></p><p class=\"\"><span>Copyright RTT News/dpa-AFX</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/dpa_afx:9a1ec4d7bd71e:0-european-stocks-close-on-mixed-note/",
            "pub_date": "2026-02-28 02:14:07",
            "source": "dpa-AFX",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L1N3ZN0ZI:0",
            "title": "Blue Owl turmoil adds to strain in $2 trillion US private credit sector",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><div class=\"summary-diQOvrPB\"><div class=\"summaryTitle-diQOvrPB\">Key points:</div><span><ul class=\"list-bmN0_SHH\"><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Blue Owl's turmoil weakens private credit sector confidence</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>AI advances threaten software companies in private credit portfolios</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Private credit market faces increased competition and valuation concerns</span></li></ul></span></div><span><p class=\"\"><span>By Saeed Azhar, Saqib Iqbal Ahmed and Matt Tracy</span></p><p class=\"\"><span>    The $2 trillion private credit industry, which has expanded over the past decade from financing leveraged buyouts to areas banks dominated, is facing fresh strain from turmoil at Blue Owl Capital, a major private lender.</span></p><p class=\"\"><span>Sentiment was already hit by questions about valuation and transparency, and specific situations such as the bankruptcy of auto-parts supplier First Brands, which some private credit players had exposure to. </span></p><p class=\"\"><span>Concerns have been compounded by troubles at Blue Owl </span><span>, which emerged late last year when it moved to limit withdrawals from a fund. In recent days, the firm has worried investors by selling shares of other alternative asset managers.</span></p><p class=\"\"><span>The collapse of UK mortgage provider Market Financial Solutions is adding to wider concerns about lending standards and the fast-growing market for private finance.</span></p><p class=\"\"><span>Some say the industry's size is working against it. State Street estimates the addressable market for private credit has grown to more than $40 trillion, including investment-grade credit.</span></p><p class=\"\"><span>\"Private credit's golden era is not over yet, but the days of generating equity-like returns might be,\" said Kyle Walters, U.S. private equity analyst at PitchBook. \"Moreover, private credit has reached a certain scale in recent years, leading to more players entering the asset class and increasing competition.\"</span></p><figure class=\"container-CvWHk7Ya\"><button class=\"previewButton-CvWHk7Ya\"><div class=\"preview-gDIex6UB fixedHeight-gDIex6UB preview-CvWHk7Ya\" style=\"height:inherit;margin:0 auto;max-height:600px;max-width:752.3510971786834px;aspect-ratio:1.2539184952978057\"><picture class=\"picture-gDIex6UB\"><source src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-316702bdb465dad7f2971d896e6f2401-resized.webp\" type=\"image/webp\"/><img alt=\"Stacked column chart showing private credit AUM to double by 2030\" class=\"image-gDIex6UB image-CvWHk7Ya\" loading=\"lazy\" role=\"presentation\" src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-316702bdb465dad7f2971d896e6f2401-resized.webp\" style=\"background-color:#f2dcd5\"/></picture></div></button><figcaption class=\"caption-CvWHk7Ya\"><span class=\"copyright-CvWHk7Ya\">Thomson Reuters</span><span class=\"description-CvWHk7Ya\">Private credit AUM to double by 2030</span></figcaption></figure><p class=\"\"><span>BLUE OWL PAIN  </span></p><p class=\"\"><span>Blue Owl's turmoil matters well beyond the firm itself because of its scale, role in private credit markets, and close ties with institutional investors, corporate borrowers and wealthy individuals. </span></p><p class=\"\"><span>The firm, which managed more than $300 billion in assets as of December 31,  said last week it would sell $1.4 billion of assets across three funds, return part of the proceeds to some investors and pay down debt. It permanently removed an option for investors in the smallest vehicle, mainly wealthy individuals, to withdraw some funds every quarter.</span></p><p class=\"\"><span>Blue Owl declined to comment, but pointed to an earlier statement that it is accelerating the return of capital to investors within the timeframe announced at the offering.</span></p><p class=\"\"><span>Credit rating firm Moody's said Blue Owl's latest decision to pivot away from traditional quarterly redemptions has sharpened investor focus on how semi‑liquid private credit vehicles manage redemptions, especially with growing retail participation.</span></p><figure class=\"container-CvWHk7Ya\"><button class=\"previewButton-CvWHk7Ya\"><div class=\"preview-gDIex6UB fixedHeight-gDIex6UB preview-CvWHk7Ya\" style=\"height:inherit;margin:0 auto;max-height:600px;max-width:770.3435804701628px;aspect-ratio:1.2839059674502713\"><picture class=\"picture-gDIex6UB\"><source src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-c51b2be41c095cab56275c82507c4151-resized.webp\" type=\"image/webp\"/><img alt=\"Grouped column chart showing Private Credit expansion into consumer ABS is expected to continue, according to estimates by Moody’s Rating\" class=\"image-gDIex6UB image-CvWHk7Ya\" loading=\"lazy\" role=\"presentation\" src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-c51b2be41c095cab56275c82507c4151-resized.webp\" style=\"background-color:#f4e4de\"/></picture></div></button><figcaption class=\"caption-CvWHk7Ya\"><span class=\"copyright-CvWHk7Ya\">Thomson Reuters</span><span class=\"description-CvWHk7Ya\">Powering on</span></figcaption></figure><p class=\"\"><span>\"Retail investors tend to be less patient and predictable than institutional investors,\" said Johannes Moller, vice president for Moody's Ratings, in a report on Tuesday. </span></p><p class=\"\"><span>Moller said rising redemption pressure is showing up across the private credit market — including at perpetual non‑traded loan vehicles, or BDCs, which offer retail and high-net-worth investors access to private credit — amid concerns about valuations and liquidity terms. </span></p><p class=\"\"><span>As alternative managers push further into the retail channel, Moody's expects liquidity management, disclosure, and fund structure design to become more central to investor decision‑making — and potentially a drag on returns. </span></p><p class=\"\"><span>Blue Owl shares are down 29% year to date, while other major alternative asset managers are also lower. Shares of Blackstone </span><span> are down nearly 27%, Apollo Global Management </span><span> is down over 26% and Ares Management </span><span> is down almost 31% this year.</span></p><figure class=\"container-CvWHk7Ya\"><button class=\"previewButton-CvWHk7Ya\"><div class=\"preview-gDIex6UB fixedHeight-gDIex6UB preview-CvWHk7Ya\" style=\"height:inherit;margin:0 auto;max-height:600px;max-width:887.5px;aspect-ratio:1.4791666666666667\"><picture class=\"picture-gDIex6UB\"><source src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-9ffc34e911874bb769ea06e98309decc-resized.webp\" type=\"image/webp\"/><img alt=\"Alt asset managers stock performance in past 12 months\" class=\"image-gDIex6UB image-CvWHk7Ya\" loading=\"lazy\" role=\"presentation\" src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-9ffc34e911874bb769ea06e98309decc-resized.webp\" style=\"background-color:#eeedec\"/></picture></div></button><figcaption class=\"caption-CvWHk7Ya\"><span class=\"copyright-CvWHk7Ya\">Thomson Reuters</span><span class=\"description-CvWHk7Ya\">Alt asset managers stock performance in past 12 months</span></figcaption></figure><p class=\"\"><span>Blackstone and Ares declined to comment, but pointed to recent comments by senior executives. Apollo did not respond to a request for comment.</span></p><p class=\"\"><span>\"We enter 2026 in a position of strength,\" said Ares CEO Michael Arougheti on the company's earnings call, citing strong underlying performance across the portfolio, and improving capital markets and M&amp;A backdrop.</span></p><p class=\"\"><span>Blackstone CFO Michael Chae said at a financial conference this month credit quality remains strong, but cautioned about an increase in defaults for the industry from an extremely low level.    </span></p><p class=\"\"><span>\"The structural advantages will continue to produce superior results. So, overall, outstanding momentum to our credit business as we move into 2026,\" he said.</span></p><p class=\"\"><span>SOFTWARE EXPOSURE STRESS  </span></p><p class=\"\"><span>Shares of other private equity firms and alternative asset managers are also facing mounting unease over valuations of software companies that they own and lend to, as artificial intelligence threatens to upend business models.</span></p><p class=\"\"><span>\"It’s not clear that things have fundamentally changed, but there’s an idea that there's a technology risk that may not have been fully priced in or contemplated as recently as three, six, or 12 months ago,\" said Christian Hoffmann, head of fixed income at Thornburg Investment Management.</span></p><p class=\"\"><span>INDUSTRY GROWTH </span></p><p class=\"\"><span>     The private credit industry has evolved from providing direct loans to middle-market companies to asset-backed finance — loans backed by collateral such as hard assets.</span></p><p class=\"\"><span>   Banks have also announced their private credit foray with JPMorgan Chase </span><span> setting aside $50 billion for its direct lending push last year, while others have partnered with alternative asset managers on private credit strategies. </span></p><figure class=\"container-CvWHk7Ya\"><button class=\"previewButton-CvWHk7Ya\"><div class=\"preview-gDIex6UB fixedHeight-gDIex6UB preview-CvWHk7Ya\" style=\"height:inherit;margin:0 auto;max-height:600px;max-width:763.4408602150538px;aspect-ratio:1.2724014336917564\"><picture class=\"picture-gDIex6UB\"><source src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-9ee6dce7b0bd09d30a459ab14fcfcfc5-resized.webp\" type=\"image/webp\"/><img alt=\"Donut charts showing Total investments by U.S. life insurers &amp; U.S. P/C insurers\" class=\"image-gDIex6UB image-CvWHk7Ya\" loading=\"lazy\" role=\"presentation\" src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-9ee6dce7b0bd09d30a459ab14fcfcfc5-resized.webp\" style=\"background-color:#f3d0c0\"/></picture></div></button><figcaption class=\"caption-CvWHk7Ya\"><span class=\"copyright-CvWHk7Ya\">Thomson Reuters</span><span class=\"description-CvWHk7Ya\">Total investments by U.S. life insurers &amp; U.S. P/C insurers</span></figcaption></figure><p class=\"\"><span>A recent Moody's report showed U.S. banks had lent nearly $300 billion to private credit providers as of June 2025. Banks loaned a further $285 billion to private equity funds and had $340 billion in unutilized bank lending commitments available to these borrowers. </span></p><figure class=\"container-CvWHk7Ya\"><button class=\"previewButton-CvWHk7Ya\"><div class=\"preview-gDIex6UB fixedHeight-gDIex6UB preview-CvWHk7Ya\" style=\"height:inherit;margin:0 auto;max-height:600px;max-width:805.2930056710775px;aspect-ratio:1.3421550094517958\"><picture class=\"picture-gDIex6UB\"><source src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-56ecaf23a167714a0413b93cfa4cff78-resized.webp\" type=\"image/webp\"/><img alt=\"Bar chart showing US banks’ private credit loan exposure\" class=\"image-gDIex6UB image-CvWHk7Ya\" loading=\"lazy\" role=\"presentation\" src=\"https://s3.tradingview.com/news/image/tag:reuters.com,2026:newsml_L1N3ZN0ZI-56ecaf23a167714a0413b93cfa4cff78-resized.webp\" style=\"background-color:#f2d7ca\"/></picture></div></button><figcaption class=\"caption-CvWHk7Ya\"><span class=\"copyright-CvWHk7Ya\">Thomson Reuters</span><span class=\"description-CvWHk7Ya\">US banks’ private credit loan exposure</span></figcaption></figure><p class=\"\"><span>Moody's has projected the industry's size to double to $4 trillion by 2030, but cautioned deepening ties between private credit funds and traditional financial institutions could heighten contagion risk in a downturn. </span></p><p class=\"\"><span>JPMorgan said this week it was watching the private credit market closely.</span></p><p class=\"\"><span>\"I'm shocked that people are shocked. The reality is in this environment, as the world gets more volatile, as you get towards the end of the cycle, this outcome should be expected,\" Troy Rohrbaugh, co-CEO of JPMorgan Chase's commercial and investment bank, told investors on Monday, referring to private credit concerns.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L1N3ZN0ZI:0-blue-owl-turmoil-adds-to-strain-in-2-trillion-us-private-credit-sector/",
            "pub_date": "2026-02-28 02:14:32",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008837:0",
            "title": "Targa Resources Is Maintained at Outperform by RBC Capital",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008837:0/",
            "pub_date": "2026-02-28 02:15:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-27:newsml_RSa8037Ua:0",
            "title": "REG - FRP Advisory Grp PLC - Holding(s) in Company",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 8037U  FRP Advisory Group PLC  27 February 2026   </span><p class=\"\"><span>TR-1: Standard form for notification of major holdings</span></p><p class=\"\"><span>1. Issuer Details</span></p><p class=\"\"><span>ISIN</span></p><p class=\"\"><span>GB00BL9BW044</span></p><p class=\"\"><span>Issuer Name</span></p><p class=\"\"><span>FRP ADVISORY GROUP PLC</span></p><p class=\"\"><span>UK or Non-UK Issuer</span></p><p class=\"\"><span>UK</span></p><p class=\"\"><span>2. Reason for Notification</span></p><p class=\"\"><span>An acquisition or disposal of voting rights</span></p><p class=\"\"><span>3. Details of person subject to the notification obligation</span></p><p class=\"\"><span>Name</span></p><p class=\"\"><span>Raymond James Wealth Management Limited</span></p><p class=\"\"><span>City of registered office (if applicable)</span></p><p class=\"\"><span>London</span></p><p class=\"\"><span>Country of registered office (if applicable)</span></p><p class=\"\"><span>United Kingdom</span></p><p class=\"\"><span>4. Details of the shareholder</span></p><p class=\"\"><span>Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above</span></p><p class=\"\"><span>City of registered office (if applicable)</span></p><p class=\"\"><span>Country of registered office (if applicable)</span></p><p class=\"\"><span>5. Date on which the threshold was crossed or reached</span></p><p class=\"\"><span>26-Feb-2026</span></p><p class=\"\"><span>6. Date on which Issuer notified</span></p><p class=\"\"><span>27-Feb-2026</span></p><p class=\"\"><span>7. Total positions of person(s) subject to the notification obligation</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td></td><td><p class=\"\"><span>% of voting rights attached to shares (total of 8.A)</span></p></td><td><p class=\"\"><span>% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)</span></p></td><td><p class=\"\"><span>Total of both in % (8.A + 8.B)</span></p></td><td><p class=\"\"><span>Total number of voting rights held in issuer</span></p></td></tr><tr><td><p class=\"\"><span>Resulting situation on the date on which threshold was crossed or reached</span></p></td><td><p class=\"\"><span>5.020000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>5.020000</span></p></td><td><p class=\"\"><span>13020414</span></p></td></tr><tr><td><p class=\"\"><span>Position of previous notification (if applicable)</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td></td></tr></tbody></table></div><p class=\"\"><span>8. Notified details of the resulting situation on the date on which the threshold was crossed or reached</span></p><p class=\"\"><span>8A. Voting rights attached to shares</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Class/Type of shares ISIN code(if possible)</span></p></td><td><p class=\"\"><span>Number of direct voting rights (DTR5.1)</span></p></td><td><p class=\"\"><span>Number of indirect voting rights (DTR5.2.1)</span></p></td><td><p class=\"\"><span>% of direct voting rights (DTR5.1)</span></p></td><td><p class=\"\"><span>% of indirect voting rights (DTR5.2.1)</span></p></td></tr><tr><td><p class=\"\"><span>GB00BL9BW044</span></p></td><td><p class=\"\"><span>13020414</span></p></td><td><p class=\"\"><span>0</span></p></td><td><p class=\"\"><span>5.020000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td></tr><tr><td><p class=\"\"><span>Sub Total 8.A</span></p></td><td colspan=\"2\"><p class=\"\"><span>13020414</span></p></td><td colspan=\"2\"><p class=\"\"><span>5.020000%</span></p></td></tr></tbody></table></div><p class=\"\"><span>8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Type of financial instrument</span></p></td><td><p class=\"\"><span>Sub Total 8.B1</span></p></td></tr><tr><td><p class=\"\"><span>Expiration date</span></p></td><td colspan=\"2\"></td></tr><tr><td><p class=\"\"><span>Exercise/conversion period</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Number of voting rights that may be acquired if the instrument is exercised/converted</span></p></td><td></td></tr><tr><td><p class=\"\"><span>% of voting rights</span></p></td></tr></tbody></table></div><p class=\"\"><span>8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Type of financial instrument</span></p></td><td><p class=\"\"><span>Sub Total 8.B2</span></p></td></tr><tr><td><p class=\"\"><span>Expiration date</span></p></td><td colspan=\"3\"></td></tr><tr><td><p class=\"\"><span>Exercise/conversion period</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Physical or cash settlement</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Number of voting rights</span></p></td></tr><tr><td><p class=\"\"><span>% of voting rights</span></p></td></tr></tbody></table></div><p class=\"\"><span>9. Information in relation to the person subject to the notification obligation</span></p><p class=\"\"><span>2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Ultimate controlling person</span></p></td><td><p class=\"\"><span>Name of controlled undertaking</span></p></td><td><p class=\"\"><span>% of voting rights if it equals or is higher than the notifiable threshold</span></p></td><td><p class=\"\"><span>% of voting rights through financial instruments if it equals or is higher than the notifiable threshold</span></p></td><td><p class=\"\"><span>Total of both if it equals or is higher than the notifiable threshold</span></p></td></tr><tr><td><p class=\"\"><span>Charles Stanley Group Plc</span></p></td><td><p class=\"\"><span>Charles Stanley Group Plc</span></p></td><td><p class=\"\"><span>5.100000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>5.100000%</span></p></td></tr><tr><td><p class=\"\"><span>Raymond James Wealth Management LTD</span></p></td><td><p class=\"\"><span>Raymond James Wealth Management LTD</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>4.990000%</span></p></td></tr><tr><td><p class=\"\"><span>Raymond James Wealth Management LTD</span></p></td><td><p class=\"\"><span>Raymond James Wealth Management LTD</span></p></td><td><p class=\"\"><span>5.020000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>5.020000%</span></p></td></tr></tbody></table></div><p class=\"\"><span>10. In case of proxy voting</span></p><p class=\"\"><span>Name of the proxy holder</span></p><p class=\"\"><span>The number and % of voting rights held</span></p><p class=\"\"><span>The date until which the voting rights will be held</span></p><p class=\"\"><span>11. Additional Information</span></p><p class=\"\"><span>12. Date of Completion</span></p><p class=\"\"><span>27/02/2026</span></p><p class=\"\"><span>13. Place Of Completion</span></p><p class=\"\"><span>London, UK</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  HOLUBRWRNBUUUAR</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-27:newsml_RSa8037Ua:0-reg-frp-advisory-grp-plc-holding-s-in-company/",
            "pub_date": "2026-02-28 02:15:00",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008836:0",
            "title": "NexPoint Residential Cut to Underperform From Market Perform by Raymond James",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008836:0/",
            "pub_date": "2026-02-28 02:15:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "stocktwits:377ce6161094b:0",
            "title": "Nio Hits New ES8 Delivery Milestone As It Gears Up To Record First Quarterly Profit From Operations",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><div class=\"summary-diQOvrPB\"><div class=\"summaryTitle-diQOvrPB\">Key points:</div><span><ul class=\"list-bmN0_SHH\"><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>In the fourth-quarter of 2025, the first full quarter of the new ES8, Nio delivered 124,807 vehicles, reaching a new quarterly record and representing an increase of 71.7% year-over-year.</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Nio is now expected to announce its financial results for the fourth-quarter on March 10.</span></li><li class=\"listItem-bmN0_SHH listItem--lightning-bmN0_SHH\"><span>Earlier this month, the EV maker said that the company is expected to achieve an adjusted profit from operations in the range of approximately RMB700 million to RMB1,200 million for Q4 2025.</span></li></ul></span></div><span><p class=\"\"><span>Nio Inc. (NIO) CEO William Li on Friday said that the company delivered its 70,000th new ES8 vehicle in the Zhejiang province, marking a new milestone for the vehicle which has driven delivery volume over the past several months.</span></p><p class=\"\"><span>“As one of NIO's core market, the All-New ES8 led large-SUV sales in eight cities across the province this January — on average 2 out of every 5 large SUVs sold were All-New ES8s,” the CEO said in a post on X.https://x.com/WilliamLiNIO/status/2027370677481996569?s=20</span></p><p class=\"\"><span>The announcement comes on the heels of the company outlining plans to launch a third-generation of its entry-level SUV ES6 in the third-quarter of 2027. Nio’s co-founder and President Qin Lihong has reportedly </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://stocktwits.com/news-articles/markets/equity/nio-stock-cant-break-higher-turns-to-suv-refresh-to-reignite-growth/cZTcONBRIRD\" rel=\"nofollow\" target=\"_blank\">said</a><span> that the company expects the revamped ES6 to be the most popular model in the third-generation lineup.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>ES8 Drives Delivery Numbers</span></strong></p><p class=\"\"><span>The ES8 is currently Nio’s best-selling SUV. The company crossed the 60,000 delivery milestone for the new three-row electric SUV in early February after deliveries began in Sept. 2025. The latest iteration of the ES8 reached 10,000 deliveries in just 41 days, and crossed 40,000 units within 100 days.</span></p><p class=\"\"><span>In the fourth-quarter of 2025, the first full quarter of the new ES8, Nio delivered 124,807 vehicles, reaching a new quarterly record and representing an increase of 71.7% year-over-year.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Nio Q4 Earnings</span></strong></p><p class=\"\"><span>Nio is now expected to announce its financial results for the fourth quarter on March 10. </span></p><p class=\"\"><span>Earlier this month, the EV maker </span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://stocktwits.com/news-articles/markets/equity/nio-stock-rallies-for-second-consecutive-day-on-quarterly-profit/cZbFZr9R4Fm\" rel=\"nofollow\" target=\"_blank\">said</a><span>, based on a preliminary assessment, that the company is expected to achieve an adjusted profit from operations in the range of approximately RMB700 million ($102.07 million) to RMB1,200 million for Q4 2025, due to growth in sales volume, optimization of vehicle margin, and cost reduction efforts. This marks the first time that the EV maker is expecting an adjusted profit from operations on a quarterly basis.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>How Did Stocktwits Users React?</span></strong></p><p class=\"\"><span>On Stocktwits, retail sentiment around NIO stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</span></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://stocktwits.com/symbol/NIO\" rel=\"nofollow\" target=\"_blank\">NIO stock</a><span> has gained 2% over the past 12 months.</span></p><p class=\"\"><em><span>Exchange Rate: RMB1= $0.15</span></em></p></span></div></div>",
            "link": "https://www.tradingview.com/news/stocktwits:377ce6161094b:0/",
            "pub_date": "2026-02-28 02:15:07",
            "source": "Stocktwits",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZN1R3:0",
            "title": "UnitedHealth caps employee pay raises to 2%, Bloomberg News reports",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>    UnitedHealth Group </span><span> has limited employee pay raises this year to between 0% and 2%, depending on performance, Bloomberg News reported on Friday, citing a person familiar with the matter.</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The modest compensation increases come as the company recently told an unspecified number of workers they were being laid off, Bloomberg reported, citing the person.      </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>UnitedHealth did not immediately respond to a Reuters request for comment.      </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company earlier this year         said         2026 revenue would decline for the first time in decades.      </span></p></li><li class=\"listItem-bmN0_SHH\"><p class=\"\"><span>The company's shares were also pressured after the Trump administration proposed a much smaller-than-expected increase to 2027 Medicare Advantage rates.      </span></p></li></ul></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZN1R3:0-unitedhealth-caps-employee-pay-raises-to-2-bloomberg-news-reports/",
            "pub_date": "2026-02-28 02:06:54",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008729:0",
            "title": "Ingevity Is Maintained at Equal-Weight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:07 GMT) </span></strong><span>Ingevity Price Target Raised to $75.00/Share From $65.00 by Wells Fargo</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008729:0/",
            "pub_date": "2026-02-28 02:07:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008731:0",
            "title": "Ardagh Metal Packaging Is Maintained at Equal-Weight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:07 GMT) </span></strong><span>Ardagh Metal Packaging Price Target Raised to $5.00/Share From $4.00 by Wells Fargo</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008731:0/",
            "pub_date": "2026-02-28 02:07:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZN1S7:0",
            "title": "Measles cases in South Carolina rise by 6 to 985",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>Measles cases in South Carolina surged to 985 on Friday, state health data showed, including six additional infections since Tuesday.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZN1S7:0-measles-cases-in-south-carolina-rise-by-6-to-985/",
            "pub_date": "2026-02-28 02:07:06",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008740:0",
            "title": "Kinder Morgan Is Maintained at Sector Perform by RBC Capital",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008740:0/",
            "pub_date": "2026-02-28 02:08:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008738:0",
            "title": "Cable One Is Maintained at Underweight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008738:0/",
            "pub_date": "2026-02-28 02:08:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-27:newsml_RSa8036Ua:0",
            "title": "REG - FTSE Russell - 3 3/4% Treasury Gilt 2027",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 8036U  FTSE Russell  27 February 2026   </span><p class=\"\"><span>Shortener: 3 3/4% Treasury Gilt 2027</span></p><p class=\"\"><span> Changes to FTSE Indices</span></p><p class=\"\"><span>27 February 2026</span></p><p class=\"\"></p><p class=\"\"><span>With the imminent shortening of maturity of 3 3/4% Treasury Gilt 2027 (BPSNB46, GB00BPSNB460), please see details of affected indices and effective dates below:</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Index</span></p></td><td><p class=\"\"><span>FTSE Actuaries UK Conventional Gilts Yield Indices</span></p></td></tr><tr><td><p class=\"\"><span>Change</span></p></td><td><p class=\"\"><span>3 3/4% Treasury Gilt 2027 (BPSNB46, GB00BPSNB460) will be deleted from the index.</span></p></td></tr><tr><td><p class=\"\"><span>Effective From</span></p><p class=\"\"><span>Start of Trading</span></p></td><td><p class=\"\"><span>06 March 2026</span></p></td></tr></tbody></table></div><p class=\"\"></p><p class=\"\"><span>For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Australia</span></p></td><td><p class=\"\"><span>+61 (0) 2 7228 5659</span></p></td></tr><tr><td><p class=\"\"><span>Hong Kong</span></p></td><td><p class=\"\"><span>+852 2164 3333</span></p></td></tr><tr><td><p class=\"\"><span>Japan</span></p></td><td><p class=\"\"><span>+81 3 6441 1430</span></p></td></tr><tr><td><p class=\"\"><span>London</span></p></td><td><p class=\"\"><span>+44 (0) 20 7866 1810</span></p></td></tr><tr><td><p class=\"\"><span>New York</span></p></td><td><p class=\"\"><span>+1877 503 6437</span></p></td></tr></tbody></table></div><p class=\"\"><span>Alternatively, please visit our website at lseg.com/ftse-russell</span></p><p class=\"\"><span> Terms of Use | Copyright © 2026 FTSE Russell</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  FTSGZGZZRNVGVZM</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-27:newsml_RSa8036Ua:0-reg-ftse-russell-3-3-4-treasury-gilt-2027/",
            "pub_date": "2026-02-28 02:08:48",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-27:newsml_RSa8035Ua:0",
            "title": "REG - FRP Advisory Grp PLC - Holding(s) in Company",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 8035U  FRP Advisory Group PLC  27 February 2026   </span><p class=\"\"><span>TR-1: Standard form for notification of major holdings</span></p><p class=\"\"><span>1. Issuer Details</span></p><p class=\"\"><span>ISIN</span></p><p class=\"\"><span>GB00BL9BW044</span></p><p class=\"\"><span>Issuer Name</span></p><p class=\"\"><span>FRP ADVISORY GROUP PLC</span></p><p class=\"\"><span>UK or Non-UK Issuer</span></p><p class=\"\"><span>UK</span></p><p class=\"\"><span>2. Reason for Notification</span></p><p class=\"\"><span>An acquisition or disposal of voting rights</span></p><p class=\"\"><span>3. Details of person subject to the notification obligation</span></p><p class=\"\"><span>Name</span></p><p class=\"\"><span>Raymond James Wealth Management Limited</span></p><p class=\"\"><span>City of registered office (if applicable)</span></p><p class=\"\"><span>London</span></p><p class=\"\"><span>Country of registered office (if applicable)</span></p><p class=\"\"><span>United Kingdom</span></p><p class=\"\"><span>4. Details of the shareholder</span></p><p class=\"\"><span>Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above</span></p><p class=\"\"><span>City of registered office (if applicable)</span></p><p class=\"\"><span>Country of registered office (if applicable)</span></p><p class=\"\"><span>5. Date on which the threshold was crossed or reached</span></p><p class=\"\"><span>23-Feb-2026</span></p><p class=\"\"><span>6. Date on which Issuer notified</span></p><p class=\"\"><span>24-Feb-2026</span></p><p class=\"\"><span>7. Total positions of person(s) subject to the notification obligation</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td></td><td><p class=\"\"><span>% of voting rights attached to shares (total of 8.A)</span></p></td><td><p class=\"\"><span>% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)</span></p></td><td><p class=\"\"><span>Total of both in % (8.A + 8.B)</span></p></td><td><p class=\"\"><span>Total number of voting rights held in issuer</span></p></td></tr><tr><td><p class=\"\"><span>Resulting situation on the date on which threshold was crossed or reached</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>12945414</span></p></td></tr><tr><td><p class=\"\"><span>Position of previous notification (if applicable)</span></p></td><td><p class=\"\"><span>5.100000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>5.100000</span></p></td><td></td></tr></tbody></table></div><p class=\"\"><span>8. Notified details of the resulting situation on the date on which the threshold was crossed or reached</span></p><p class=\"\"><span>8A. Voting rights attached to shares</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Class/Type of shares ISIN code(if possible)</span></p></td><td><p class=\"\"><span>Number of direct voting rights (DTR5.1)</span></p></td><td><p class=\"\"><span>Number of indirect voting rights (DTR5.2.1)</span></p></td><td><p class=\"\"><span>% of direct voting rights (DTR5.1)</span></p></td><td><p class=\"\"><span>% of indirect voting rights (DTR5.2.1)</span></p></td></tr><tr><td><p class=\"\"><span>GB00BL9BW044</span></p></td><td><p class=\"\"><span>12945414</span></p></td><td><p class=\"\"><span>0</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td></tr><tr><td><p class=\"\"><span>Sub Total 8.A</span></p></td><td colspan=\"2\"><p class=\"\"><span>12945414</span></p></td><td colspan=\"2\"><p class=\"\"><span>4.990000%</span></p></td></tr></tbody></table></div><p class=\"\"><span>8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Type of financial instrument</span></p></td><td><p class=\"\"><span>Sub Total 8.B1</span></p></td></tr><tr><td><p class=\"\"><span>Expiration date</span></p></td><td colspan=\"2\"></td></tr><tr><td><p class=\"\"><span>Exercise/conversion period</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Number of voting rights that may be acquired if the instrument is exercised/converted</span></p></td><td></td></tr><tr><td><p class=\"\"><span>% of voting rights</span></p></td></tr></tbody></table></div><p class=\"\"><span>8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Type of financial instrument</span></p></td><td><p class=\"\"><span>Sub Total 8.B2</span></p></td></tr><tr><td><p class=\"\"><span>Expiration date</span></p></td><td colspan=\"3\"></td></tr><tr><td><p class=\"\"><span>Exercise/conversion period</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Physical or cash settlement</span></p></td><td></td></tr><tr><td><p class=\"\"><span>Number of voting rights</span></p></td></tr><tr><td><p class=\"\"><span>% of voting rights</span></p></td></tr></tbody></table></div><p class=\"\"><span>9. Information in relation to the person subject to the notification obligation</span></p><p class=\"\"><span>2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Ultimate controlling person</span></p></td><td><p class=\"\"><span>Name of controlled undertaking</span></p></td><td><p class=\"\"><span>% of voting rights if it equals or is higher than the notifiable threshold</span></p></td><td><p class=\"\"><span>% of voting rights through financial instruments if it equals or is higher than the notifiable threshold</span></p></td><td><p class=\"\"><span>Total of both if it equals or is higher than the notifiable threshold</span></p></td></tr><tr><td><p class=\"\"><span>Charles Stanley Group Plc</span></p></td><td><p class=\"\"><span>Charles Stanley Group Plc</span></p></td><td><p class=\"\"><span>5.100000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>5.100000%</span></p></td></tr><tr><td><p class=\"\"><span>Raymond James Wealth Management LTD</span></p></td><td><p class=\"\"><span>Raymond James Wealth Management LTD</span></p></td><td><p class=\"\"><span>4.990000</span></p></td><td><p class=\"\"><span>0.000000</span></p></td><td><p class=\"\"><span>4.990000%</span></p></td></tr></tbody></table></div><p class=\"\"><span>10. In case of proxy voting</span></p><p class=\"\"><span>Name of the proxy holder</span></p><p class=\"\"><span>The number and % of voting rights held</span></p><p class=\"\"><span>The date until which the voting rights will be held</span></p><p class=\"\"><span>11. Additional Information</span></p><p class=\"\"><span>12. Date of Completion</span></p><p class=\"\"><span>24/02/2026</span></p><p class=\"\"><span>13. Place Of Completion</span></p><p class=\"\"><span>London, UK</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  HOLUBRWRNVUUUAR</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-27:newsml_RSa8035Ua:0-reg-frp-advisory-grp-plc-holding-s-in-company/",
            "pub_date": "2026-02-28 02:08:57",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008750:0",
            "title": "Zscaler Is Maintained at Outperform by Mizuho",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:09 GMT) </span></strong><span>Zscaler Price Target Cut to $250.00/Share From $265.00 by Mizuho</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008750:0/",
            "pub_date": "2026-02-28 02:09:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008746:0",
            "title": "PACS Group Is Maintained at Outperform by RBC Capital",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:09 GMT) </span></strong><span>PACS Group Price Target Raised to $52.00/Share From $47.00 by RBC Capital</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008746:0/",
            "pub_date": "2026-02-28 02:09:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008748:0",
            "title": "Nexstar Media Is Maintained at Overweight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span class=\"placeholder-diQOvrPB\">This news item displays a headline only and has no other text.</span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008748:0/",
            "pub_date": "2026-02-28 02:09:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZN1RD:0",
            "title": "Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div><span><p class=\"\"><span>Flagship-backed Generate Biomedicines' (GENB.O) shares fell 6.25% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings.</span></p><p class=\"\"><span>The Somerville, Massachusetts-based company's shares opened at $15, compared with its IPO price of $16. It raised $400 million in its U.S. initial public offering on Thursday, after selling 25 million shares within its marketed range of $15 to $17 apiece. </span></p><p class=\"\"><span>Biotech IPOs have gained momentum as interest rates ease and capital returns to the sector, but the recovery remains uneven, with investors staying selective.</span></p><p class=\"\"><span>Eikon Therapeutics (EIKN.O) and Agomab Therapeutics (AGMB.O), health-sector companies that have recently done IPOs, are both trading below their offer prices as of last close.</span></p><p class=\"\"><span>Generate Biomedicines, which describes itself as a pioneer in applying artificial intelligence to biotechnology and drug design, plans to use much of the IPO’s proceeds to complete two Phase 3 trials of its lead asthma drug, GB‑0895.</span></p><p class=\"\"><span>Its early work includes GB‑0669, a COVID‑19 antibody that showed broad, variant‑resistant activity, though the company has shelved its development in light of changing market conditions for preventive COVID‑19 therapies.</span></p><p class=\"\"><span>Noubar Afeyan, who co-founded drugmaker Moderna and is among the board chairs of Generate, is expected to control 49% of the shares through investment firm Flagship Pioneering. The board also includes Nobel laureate Frances Arnold and Moderna CEO Stéphane Bancel.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZN1RD:0-generate-biomedicines-shares-fall-6-in-weak-nasdaq-debut-for-drug-developer/",
            "pub_date": "2026-02-28 02:09:09",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "modular_finance:25ddb55b87dec:0",
            "title": "Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB (publ)",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Aktieägarna i ExpreS2ion Biotech Holding AB (publ),</span></strong><strong class=\"root-Tkn6WL2y\"><span>org.nr</span></strong><strong class=\"root-Tkn6WL2y\"><span>559033-3729 (\"Bolaget\"), kallas härmed till extra bolagsstämma den 1 april 2026 klockan 09:00 på Mindpark, Rönnowsgatan 8C i Helsingborg. Inpassering och registrering till stämman startar klockan 08:45.</span></strong></p><p class=\"\"><span>Styrelsen har, i enlighet med Bolagets bolagsordning, beslutat att aktieägarna före bolagsstämman ska ha möjlighet att utöva sin röstratt genom poströstning. Aktieägare kan därmed välja att utöva sin rösträtt vid stämman personligen, genom ombud eller genom poströstning.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Rätt att delta och anmälan</span></strong></p><p class=\"\"><span>Rätt att delta i stämman har den som:</span></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>är införd i den av Euroclear Sweden AB förda aktieboken den 24 mars 2026; och</span></li><li class=\"listItem-bmN0_SHH\"><span>anmält sin avsikt att delta vid stämman till Bolaget i enlighet med anvisningarna under rubriken ”</span><em><span>Anmälan för deltagande personligen eller genom ombud</span></em><span>” senast den 26 mars 2026 eller avget en poströst i enlighet med anvisningarna under rubriken ”</span><em><span>Anvisningar för poströstning</span></em><span>” senast den 26 mars 2026.</span></li></ul><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Förvaltarregistrerade aktier</span></strong></p><p class=\"\"><span>Aktieägare som låtit förvaltarregistrera sina aktier måste, för att få delta i extra bolagsstämman och utöva sin rösträtt, tillfälligt inregistrera aktierna i eget namn i aktieboken hos Euroclear Sweden AB (s.k. rösträttsregistrering). Framställningen av bolagsstämmoaktieboken per avstämningsdagen den 24 mars 2026 kommer att beakta rösträttsregistreringar som har gjorts senast den 26 mars 2026. Det innebär att aktieägaren i god tid före denna dag måste begära att förvaltaren genomför sådan rösträttsregistrering.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Anmälan för deltagande personligen eller genom ombud</span></strong></p><p class=\"\"><span>Den som önskar delta vid stämman personligen eller genom ombud ska anmäla detta till Bolaget senast den 26 mars 2026 till ExpreS2ion Biotech Holding AB (publ), \"EGM 2026”, c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, att: Keith Alexander, eller via e-post till</span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:investor@expres2ionbio.com\" rel=\"nofollow\" target=\"_blank\">investor@expres2ionbio.com</a><span>. Vid anmälan ska aktieägaren uppge namn, adress, telefonnummer (dagtid), person- /organisationsnummer, aktieinnehav samt antal eventuella ombud/biträden.</span></p><p class=\"\"><span>Den som inte önskar närvara personligen och inte heller utöva sin rösträtt genom poströstning får utöva sin rätt vid stämman genom ombud med skriftlig, undertecknad och daterad fullmakt. Fullmakten får inte vara äldre än ett år, såvida inte längre giltighetstid (dock längst fem år) har angivits i fullmakten. Om fullmakten utfärdats av en juridisk person ska kopia av registreringsbevis eller motsvarande behörighetshandling för den juridiska personen bifogas. För att underlätta inpasseringen vid stämman bör fullmakter, registreringsbevis och andra behörighetshandlingar skickas antingen per e-post tillinvestor@expres2ionbio.commed referensen \"EGM 2026\" alternativt per post till ExpreS2ion Biotech Holding AB (publ), ”EGM 2026”, c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, Sweden, att: Keith Alexander, senast den 26 mars 2026. Observera att anmälan om deltagande vid stämman ska ske även om aktieägaren önskar utöva sin rösträtt vid stämman genom ombud. Inskickad fullmakt gäller inte som anmälan till stämman. Fullmaktsformulär på svenska och engelska finns på Bolagets webbplats,investor.expres2ionbio.com.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Anvisningar för poströstning</span></strong></p><p class=\"\"><span>Aktieägare som önskar utöva sin rösträtt genom poströstning ska använda det poströstningsformulär och följa de anvisningar som finns tillgängliga på Bolagets webbplats,investor.expres2ionbio.com. Poströsten måste vara Bolaget tillhanda senast den 26 mars 2026. Poströstningsformuläret ska skickas till ExpreS2ion Biotech Holding AB (publ), ”EGM 2026”, c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, att: Keith Alexander, alternativt per e-post till</span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:investor@expres2ionbio.com\" rel=\"nofollow\" target=\"_blank\">investor@expres2ionbio.com</a><span>med referensen \"EGM 2026\".</span></p><p class=\"\"><span>Om aktieägare avger poströst genom ombud ska en skriftlig och daterad fullmakt biläggas poströstningsformuläret. Fullmaktsformulär tillhandhålls på begäran och finns även tillgängligt på Bolagets webbplats,investor.expres2ionbio.com. Om aktieägaren är en juridisk person ska registreringsbevis eller motsvarande behörighetshandling för den juridiska personen bifogas. Aktieägare får inte förse poströsten med särskilda instruktioner eller villkor. Om så sker är hela poströsten ogiltig. Ytterligare anvisningar och villkor finns i poströstningsformuläret.</span></p><p class=\"\"><span>För frågor om stämman eller för att erhålla ett poströstningsformulär eller ett fullmaktsformulär per post, vänligen kontakta ExpreS2ion Biotech Holding AB (publ), ”EGM 2026”, c/o Mindpark, Rönnowsgatan 8C, 252 25 Helsingborg, att: Keith Alexander, alternativt per e-post till</span><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"http://mailto:investor@expres2ionbio.com\" rel=\"nofollow\" target=\"_blank\">investor@expres2ionbio.com</a><span>.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Förslag till dagordning</span></strong></p><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Stämmans öppnande och val av ordförande vid stämman</span></li><li class=\"listItem-bmN0_SHH\"><span>Upprättande och godkännande av röstlängd</span></li><li class=\"listItem-bmN0_SHH\"><span>Val av en eller två justeringsmän</span></li><li class=\"listItem-bmN0_SHH\"><span>Prövande av om stämman blivit behörigen sammankallad</span></li><li class=\"listItem-bmN0_SHH\"><span>Godkännande av dagordning</span></li><li class=\"listItem-bmN0_SHH\"><span>Beslut om ändring av bolagsordningen samt minskning av aktiekapitalet för att möjliggöra den avsedda företrädesemissionen av units</span><ul class=\"list-bmN0_SHH list--padded-bmN0_SHH\"><li class=\"listItem-bmN0_SHH\"><span>Styrelsens förslag till beslut om ändring av § 4 i bolagsordningen</span></li><li class=\"listItem-bmN0_SHH\"><span>Styrelsens förslag till beslut om minskning av aktiekapitalet</span></li></ul></li><li class=\"listItem-bmN0_SHH\"><span>Beslut om ändring av bolagsordningen</span></li><li class=\"listItem-bmN0_SHH\"><span>Beslut om bemyndigande för styrelsen att emittera aktier, konvertibler och/eller teckningsoptioner</span></li><li class=\"listItem-bmN0_SHH\"><span>Fastställande av arvoden till styrelsen</span></li><li class=\"listItem-bmN0_SHH\"><span>Val av ny styrelseledamot</span></li><li class=\"listItem-bmN0_SHH\"><span>Stämmans avslutande</span></li></ul><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 1 – Val av ordförande vid stämman</span></strong></p><p class=\"\"><span>Styrelsen föreslår att advokat Emil Hedberg, eller vid dennes förhinder den som styrelsen i stället anvisar, ska väljas till ordförande vid stämman.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 6 – Beslut om ändring av bolagsordningen samt minskning av aktiekapitalet för att möjliggöra den avsedda företrädesemissionen av units</span></strong></p><p class=\"\"><em><span>Allmän information om styrelsens förslag enligt punkt 6</span></em></p><p class=\"\"><span>I enlighet med det pressmeddelande som Bolaget offentliggjorde den 27 februari 2026 har styrelsen för avsikt att besluta om en företrädesemission av units om cirka 53 MSEK (”</span><strong class=\"root-Tkn6WL2y\"><span>Företrädesemissionen</span></strong><span>”). Teckningskursen per unit i Företrädesemissionen ska motsvara en TERP-rabatt om minst 35 procent i relation till den volymvägda genomsnittskursen för Bolagets aktie på Nasdaq First North Growth Market under perioden från och med den 24 mars 2026 till och med den 6 april 2026, dock högst 5 SEK och inte lägre än det nya kvotvärdet för Bolagets aktie (1,6 SEK för det fall bolagsstämman beslutar i enlighet med punkt 6). För att möjliggöra genomförandet av Företrädesemissionen föreslås stämman besluta om minskning av aktiekapitalet och justering av aktiekapitalets gränser i bolagsordningen. Ärendena under punkterna 6 a) – b) utgör ett samlat förslag och ska behandlas av bolagsstämman genom ett beslut. Beslut enligt denna punkt 6 är villkorat av att stämman även beslutar enligt punkterna 7 och 8 samt att styrelsen beslutar att genomföra Företrädesemissionen.</span></p><p class=\"\"><em><span>Bemyndigande</span></em></p><p class=\"\"><span>Styrelsen, den verkställande direktören, eller den som styrelsen eller verkställande direktören utser, bemyndigas att vidta de smärre ändringar i beslutet som kan visa sig erforderliga i samband med registreringen av beslutet vid Bolagsverket eller på grund av andra formella krav.</span></p><p class=\"\"><em><span>Majoritetskrav</span></em></p><p class=\"\"><span>För giltigt beslut enligt denna punkt 6 erfordras biträde av aktieägare som representerar minst två tredjedelar av såväl de avgivna rösterna som de vid bolagsstämman företrädda aktierna.</span></p><p class=\"\"><em><strong class=\"root-Tkn6WL2y\"><span>Punkt 6 a) – Styrelsens förslag till beslut om ändring av § 4 i bolagsordningen</span></strong></em></p><p class=\"\"><em><span>För att möjliggöra aktiekapitalsminskningen under punkt 6 b) föreslår styrelsen att bolagsstämman beslutar att ändra gränserna för aktiekapitalet enligt § 4 i bolagsordningen enligt följande.</span></em></p><p class=\"\"><em><span>§ 4 i bolagsordningen föreslås erhålla följande lydelse.</span></em></p><p class=\"\"><em><span>Nuvarande lydelse</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 8 000 000 kronor och högst 32 000 000 kronor.</span></p><p class=\"\"><em><span>Föreslagen lydelse</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 5 648 372,80 kronor och högst 22 593 491,20 kronor</span><em><span>.</span></em></p><p class=\"\"><em><strong class=\"root-Tkn6WL2y\"><span>Punkt 6 b) – Styrelsens förslag till beslut om minskning av aktiekapitalet</span></strong></em></p><p class=\"\"><span>Styrelsen föreslår att bolagsstämman beslutar om minskning av Bolagets aktiekapital med 10 041 551,672912 kronor. Minskningen ska genomföras utan indragning av aktier. Minskningsbeloppet ska användas för avsättning till fritt eget kapital. Minskningen genomförs för att minska aktiernas kvotvärde och för att möjliggöra Företrädesemissionen. Efter minskningen kommer Bolagets aktiekapital att uppgå till 5 648 372,80 kronor fördelat på sammanlagt 3 530 233 aktier (före Företrädesemissionen), envar aktie med ett kvotvärde om 1,6 kronor.</span></p><p class=\"\"><em><span>Styrelsens redogörelse enligt 20 kap 13 § fjärde stycket aktiebolagslagen</span></em></p><p class=\"\"><span>Effekten av styrelsens förslag är att Bolagets aktiekapital minskar med 10 041 551,672912 kronor, från 15 689 924,472912 kronor till 5 648 372,80 kronor. Styrelsen avser samtidigt, med stöd av emissionsbemyndigandet enligt punkt 8 besluta om Företrädesemissionen om cirka 53 miljoner kronor vilken är säkerställd till cirka 60 procent. Teckningskursen per unit i Företrädesemissionen ska motsvara en TERP-rabatt om minst 35 procent i relation till den volymvägda genomsnittskursen för Bolagets aktie på Nasdaq First North Growth Market under perioden från och med den 24 mars 2026 till och med den 6 april 2026, dock högst 5 SEK och inte lägre än det nya kvotvärdet för Bolagets aktie (1,6 SEK för det fall bolagsstämman beslutar i enlighet med punkt 6). Aktiekapitalsminskningen och genomförandet av Företrädesemissionen är villkorade av varandra. Genom att genomföra Företrädesemissionen kommer aktiekapitalet i Bolaget att, i samband med att aktiekapitalsminskningen registreras vid Bolagsverket, samtidigt öka med minst det belopp som aktiekapitalet minskats med. Genom att samtidigt med minskningen genomföra Företrädesemissionen får Bolaget verkställa minskningsbeslutet utan tillstånd från Bolagsverket eller allmän domstol, eftersom åtgärderna sammantaget medför att varken Bolagets bundna egna kapital eller dess aktiekapital minskar.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 7 – Beslut om ändring av bolagsordningen</span></strong></p><p class=\"\"><span>Styrelsen föreslår att stämman beslutar om ändring av bolagsordningen enligt förslagen i punkterna 7 a), 7 b) och 7 c) nedan för att möjliggöra Företrädesemissionen.</span></p><p class=\"\"><span>Beslut enligt punkterna 7 a) - 7 c) nedan är villkorat av, och ska anmälas för registrering vid Bolagsverket efter, att Bolaget har beslutat om Företrädesemissionen. Vidare föreslår styrelsen att styrelsen bemyndigas att anmäla för registrering vid Bolagsverket den bolagsordning enligt punkt 7 a), punkt 7 b) eller punkt 7 c) vars gränser för det lägsta och högsta antalet aktier och aktiekapitalet i Bolaget är förenliga med det totala antalet aktier och aktiekapitalet i Bolaget efter att styrelsen har beslutat om Företrädesemissionen. För det fall det totala antalet aktier och aktiekapitalet i Bolaget efter att styrelsen har beslutat om Företrädesemissionen är förenlig med ändringarna av bolagsordningen enligt samtliga eller några av punkterna 7 a) - 7 c) nedan ska den bolagsordning som anger det högsta antalet aktier och aktiekapitalet i Bolaget anmälas för registrering.</span></p><p class=\"\"><span>Beslut enligt denna punkt 7 är villkorat av att stämman även beslutar i enlighet med punkterna 6 och 8.</span></p><p class=\"\"><em><span>Bemyndigande</span></em></p><p class=\"\"><span>Styrelsen, den verkställande direktören, eller den som styrelsen eller verkställande direktören utser, bemyndigas att vidta de smärre ändringar i beslutet som kan visa sig erforderliga i samband med registreringen av beslutet vid Bolagsverket eller på grund av andra formella krav.</span></p><p class=\"\"><em><span>Majoritetskrav</span></em></p><p class=\"\"><span>För giltigt beslut enligt punkterna 7 a) - c) ovan fordras att beslutet biträds av aktieägare med minst två tredjedelar av såväl de avgivna rösterna som de vid stämman företrädda aktierna.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 7 a) - Styrelsen föreslår att bolagsstämman beslutar om följande ändringar av bolagsordningens 4-5 §§.</span></strong></p><p class=\"\"><em><span>Nuvarande lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 5 648 372,80 kronor och högst 22 593 491,20 kronor</span><em><span>.</span></em></p><p class=\"\"><em><span>Föreslagen lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 13 440 000 kronor och högst 53 760 000 kronor.</span></p><p class=\"\"><em><span>Nuvarande lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 2 100 000 och högst 8 400 000.</span></p><p class=\"\"><em><span>Föreslagen lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 8 400 000 och högst 33 600 000.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 7 b) - Styrelsen föreslår att bolagsstämman beslutar om följande ändringar av bolagsordningens 4-5 §§.</span></strong></p><p class=\"\"><em><span>Nuvarande lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 5 648 372,80 kronor och högst 22 593 491,20 kronor</span><em><span>.</span></em></p><p class=\"\"><em><span>Föreslagen lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 26 880 000 kronor och högst 107 520 000 kronor.</span></p><p class=\"\"><em><span>Nuvarande lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 2 100 000 och högst 8 400 000.</span></p><p class=\"\"><em><span>Föreslagen lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 16 800 000 och högst 67 200 000.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 7 c) - Styrelsen föreslår att bolagsstämman beslutar om följande ändringar av bolagsordningens 4-5 §§.</span></strong></p><p class=\"\"><em><span>Nuvarande lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 5 648 372,80 kronor och högst 22 593 491,20 kronor</span><em><span>.</span></em></p><p class=\"\"><em><span>Föreslagen lydelse § 4:</span></em></p><p class=\"\"><span>Aktiekapitalet ska vara lägst 53 760 000 kronor och högst 215 040 000 kronor.</span></p><p class=\"\"><em><span>Nuvarande lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 2 100 000 och högst 8 400 000.</span></p><p class=\"\"><em><span>Föreslagen lydelse § 5:</span></em></p><p class=\"\"><span>Antalet aktier ska vara lägst 33 600 000 och högst 134 400 000.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 8 - Beslut om bemyndigande för styrelsen att emittera aktier, konvertibler och/eller teckningsoptioner</span></strong></p><p class=\"\"><span>Styrelsen föreslår att extra bolagsstämman beslutar att bemyndiga styrelsen att intill nästa årsstämma, vid ett eller flera tillfällen, besluta om nyemission av aktier, konvertibler och/eller teckningsoptioner, med eller utan avvikelse från aktieägares företrädesrätt, att betalas kontant, genom apport och/eller genom kvittning. Beslut som fattas med stöd av detta emissionsbemyndigande, och där teckningskursen understiger aktiernas kvotvärde per dagen för denna kallelse, är villkorade av att extra bolagsstämman även beslutar i enlighet med förslaget under punkt 6 och punkt 7 ovan och att dessa beslut samtidigt registreras vid Bolagsverket.</span></p><p class=\"\"><span>Att styrelsen ska kunna fatta beslut om emission utan företrädesrätt för aktieägarna enligt ovan är främst i syfte att kunna anskaffa nytt kapital för att bredda Bolagets ägarbas, öka Bolagets flexibilitet, erläggande av betalning för garantiåtaganden i form av units eller i samband med förvärv. I den mån emission sker med avvikelse från aktieägarnas företrädesrätt ska emissionen ske på sedvanliga marknadsmässiga villkor. Om styrelsen finner det lämpligt för att möjliggöra leverans av aktier i samband med en emission enligt ovan kan detta göras till ett teckningspris motsvarande aktiernas kvotvärde.</span></p><p class=\"\"><em><span>Bemyndigande</span></em></p><p class=\"\"><span>Styrelsen, den verkställande direktören, eller den som styrelsen eller verkställande direktören utser, bemyndigas att vidta de smärre ändringar i beslutet som kan visa sig erforderliga i samband med registreringen av beslutet vid Bolagsverket eller på grund av andra formella krav.</span></p><p class=\"\"><em><span>Majoritetskrav</span></em></p><p class=\"\"><span>För giltigt beslut enligt denna punkt 8 erfordras biträde av aktieägare som representerar minst två tredjedelar av såväl de avgivna rösterna som de vid bolagsstämman företrädda aktierna.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 9 – Fastställande av arvoden till styrelsen</span></strong></p><p class=\"\"><span>Aktieägarna Allan Rosetzsky, AR CONSULT ApS, Martin Roland Holding ApS och Medic-Advice ApS (\"</span><strong class=\"root-Tkn6WL2y\"><span>Aktieägarna</span></strong><span>\") föreslår att styrelsearvode ska utgå i enlighet med arvodesnivåerna som beslutades av årsstämman 2025, proportionerligt i förhållande till mandattidens längd.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Punkt 10 – Val av styrelseledamöter</span></strong></p><p class=\"\"><span>Aktieägarna föreslår omval av Martin Roland Jensen (ordförande), Karin Garre och Jakob Knudsen samt nyval av Michel J. Baijot som styrelseledamöter för tiden intill slutet av nästa årsstämma. Om stämman beslutar i enlighet med Aktieägarnas förslag kommer styrelsen, för tiden intill slutet av nästa årsstämma, att bestå av Martin Roland Jensen (ordförande), Karin Garre, Jakob Knudsen och Michel J. Baijot.</span></p><p class=\"\"><em><span>Information om Michel J. Baijot</span></em></p><p class=\"\"><em><span>Född:</span></em><span>1961.</span></p><p class=\"\"><em><span>Utbildning:</span></em><span>Bioingenjör, doktorsexamen i molekylärbiologi från University of Louvain (Belgien).</span></p><p class=\"\"><em><span>Bakgrund:</span></em><span>Michel Baijot har tillbringat mer än 25 år i olika ledande befattningar hos bioMerieux som Corporate Director Molecular Diagnostics, hos Innogenetics som VP of Business Development, hos GSK Vaccines som VP of strategy, licensing and M&amp;A, hos Janssen Crucell Vaccines som Chief Business Officer och hos Serum Institute of India som Executive Director Europe. Han har varit ordförande för Belgian Biotech Association i 5 år.</span></p><p class=\"\"><em><span>Pågående uppdrag</span></em><span>: Styrelseordförande i White Fund, styrelseledamot i RNAlead, Director på Noshaq samt styrelseordförande i CuraVac.</span></p><p class=\"\"><em><span>Oberoende</span></em><span>: Michel J. Baijot är oberoende i förhållande till Bolaget och Bolagets ledning samt i förhållande till Bolagets större aktieägare.</span></p><p class=\"\"><em><span>Aktieägande</span></em><span>: Michel J. Baijot innehar inga aktier i Bolaget per dagen för denna kallelse.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Handlingar</span></strong></p><p class=\"\"><span>Fullmaktsformulär, poströstningsformulär och övriga handlingar enligt aktiebolagslagen kommer att finnas tillgängliga vid Bolagets kontor på Mindpark, Bredgatan 11 i Helsingborg samt på Bolagets webbplats,www.investor.expres2ionbio.com, senast två veckor före stämman. Handlingarna skickas också till de aktieägare som önskar detta och uppger sin postadress.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Aktieägarnas frågerätt</span></strong></p><p class=\"\"><span>Aktieägarna erinras om rätten att vid stämman begära upplysningar från styrelsen och verkställande direktören i enlighet med 7 kap 32 § aktiebolagslagen.</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Behandling av personuppgifter</span></strong></p><p class=\"\"><span>För information om hur dina personuppgifter behandlas hänvisas till den integritetspolicy som finns tillgänglig på Euroclears webbplats:www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.</span></p><p class=\"\"><span>______________</span></p><p class=\"\"><span>Helsingborg i februari 2026</span></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>ExpreS2ion Biotech Holding AB (publ)</span></strong></p><p class=\"\"><em><span>Styrelsen</span></em></p><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>Attachments</span></strong></p><p class=\"\"><a class=\"link-zw5jRdec icon-zw5jRdec\" href=\"https://storage.mfn.se/30418de7-3222-49e3-8365-cd944744df8e/kallelse-till-extra-bolagsstamma-i-expres2ion-biotech-holding-ab-publ.pdf\" rel=\"nofollow\" target=\"_blank\">Kallelse till extra bolagsstämma i ExpreS2ion Biotech Holding AB (publ)</a></p></span></div></div>",
            "link": "https://www.tradingview.com/news/modular_finance:25ddb55b87dec:0-kallelse-till-extra-bolagsst-mma-i-expres2ion-biotech-holding-ab-publ/",
            "pub_date": "2026-02-28 02:10:00",
            "source": "MFN by Modular Finance",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008663:0",
            "title": "Relay Therapeutics Is Maintained at Overweight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:00 GMT) </span></strong><span>Relay Therapeutics Price Target Raised to $15.00/Share From $13.00 by Wells Fargo</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008663:0/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026-02-27:newsml_RSa7693Ua:0",
            "title": "REG - FTSE Russell Invesco Glbl. Equity - Invesco Global Equity Income Trust",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><span>RNS Number : 7693U  FTSE Russell  27 February 2026   </span><p class=\"\"></p><p class=\"\"></p><p class=\"\"><span>47</span></p><p class=\"\"><span>Franklin Global Trust (UK): Scheme of Reconstruction into Invesco Global Equity Income Trust (UK)</span></p><p class=\"\"><span>Changes in FTSE UK Index Series</span></p><p class=\"\"><span>27 February 2026</span></p><p class=\"\"></p><p class=\"\"><span>Further to the FTSE Russell notice published on 10 February 2026 and following the publication of the stock terms and election results of the scheme of reconstruction between Franklin Global Trust (UK, constituent) and Invesco Global Equity Income Trust (UK, constituent), please see details of affected indexes and effective dates below:</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><thead><tr><td><p class=\"\"><span>Index</span></p></td><td><p class=\"\"><span>Effective From</span></p><p class=\"\"><span>Start of Trading</span></p></td></tr></thead><tbody><tr><td><p class=\"\"><span>FTSE SmallCap Index</span></p></td><td><p class=\"\"><span>04 March 2026</span></p></td></tr><tr><td><p class=\"\"><span>FTSE All-Share Index</span></p></td><td><p class=\"\"><span>04 March 2026</span></p></td></tr><tr><td><p class=\"\"><span>FTSE All-Share ex Multinationals Index</span></p></td><td><p class=\"\"><span>04 March 2026</span></p></td></tr><tr><td><p class=\"\"><span>FTSE All-Small Index</span></p></td><td><p class=\"\"><span>04 March 2026</span></p></td></tr></tbody></table></div><p class=\"\"></p><p class=\"\"><span>For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:</span></p><div class=\"tableContainer-VG8_37yK\"><table class=\"table-VG8_37yK\" data-no-swipe=\"true\"><tbody><tr><td><p class=\"\"><span>Australia</span></p></td><td><p class=\"\"><span>+61 (0) 2 7228 5659</span></p></td></tr><tr><td><p class=\"\"><span>Hong Kong</span></p></td><td><p class=\"\"><span>+852 2164 3333</span></p></td></tr><tr><td><p class=\"\"><span>Japan</span></p></td><td><p class=\"\"><span>+81 3 6441 1430</span></p></td></tr><tr><td><p class=\"\"><span>London</span></p></td><td><p class=\"\"><span>+44 (0) 20 7866 1810</span></p></td></tr><tr><td><p class=\"\"><span>New York</span></p></td><td><p class=\"\"><span>+1877 503 6437</span></p></td></tr></tbody></table></div><p class=\"\"><span>Alternatively please visit our website at lseg.com/ftse-russell</span></p><p class=\"\"><span> Terms of Use | Copyright © 2026 FTSE Russell</span></p><span>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</span><p class=\"\"><span>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END  FTSBXGDDGXDDGLR</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026-02-27:newsml_RSa7693Ua:0-reg-ftse-russell-invesco-glbl-equity-invesco-global-equity-income-trust/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "London Stock Exchange",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "DJN_DN20260227008665:0",
            "title": "Natera Is Maintained at Equal-Weight by Wells Fargo",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><strong class=\"root-Tkn6WL2y\"><span>(18:00 GMT) </span></strong><span>Natera Price Target Raised to $215.00/Share From $205.00 by Wells Fargo</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/DJN_DN20260227008665:0/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "Dow Jones Newswires",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "tag:reuters.com,2026:newsml_L4N3ZM155:0",
            "title": "Mexico corporate earnings week ahead",
            "description": "<div class=\"body-KX2tCBZq body-nzzZVyQ3 content-nzzZVyQ3\"><div class=\"symbolsContainer-uFduEtAF logosContainer-diQOvrPB\" data-no-swipe=\"true\"></div><div><span><p class=\"\"><span>Please be advised that there are no corporate earnings scheduled for Mexico (.MXX) in the week ahead.</span></p></span></div></div>",
            "link": "https://www.tradingview.com/news/reuters.com,2026:newsml_L4N3ZM155:0-mexico-corporate-earnings-week-ahead/",
            "pub_date": "2026-02-28 02:00:00",
            "source": "Reuters",
            "kind": 1,
            "language": "en"
        }
    ]
}